Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 1 of 64 · 3071 articles
Subtopics
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Microbiome, and Research and clinical trials. The original article is from Communications Medicine.
This change may make starting Skyrizi more convenient for adults with Crohn's disease by allowing subcutaneous induction at home using an on‑body injector, rather than requiring clinic IV infusions. It also represents an...
MSC therapy and its interaction with autophagy could point to new ways to boost cell-based treatments for IBD. For people with Crohn's disease or ulcerative colitis, this could eventually lead to different therapeutic...
The paper describes a plant-derived polysaccharide that reduced inflammation, improved barrier proteins, and shifted gut microbiota in a mouse model of ulcerative colitis—mechanisms relevant to IBD. If replicated and...
If probiotic strains can increase beneficial microbial metabolites that strengthen the gut barrier and reduce inflammation, they could point to new adjunctive strategies for IBD treatment.
A transcriptomic "barrier-injury" score that tracks mucosal inflammation and predicts lower odds of mucosal healing could help researchers develop biomarkers for patient stratification, prognosis, or as exploratory...
The study suggests commonly available lab tests might help identify intestinal fibrosis and strictures in Crohn’s disease using a five-marker blood-based model, which could offer a noninvasive screening option if...
A formulation that targets and sustains budesonide release in the intestine could improve local anti-inflammatory effects and reduce systemic exposure compared with standard oral formulations. If translational studies...
The study identifies a TSPO-targeting compound (koumine) that improved disease and intestinal barrier function in mouse models of ulcerative colitis and links the effect to changes in energy metabolism—an emerging area...
The study suggests a specific mechanism—modulation of the SphK1/S1P/NF-κB pathway—by which components of a traditional herbal formula may reduce intestinal inflammation and influence the gut microbiome. If validated in...
The paper points to a specific RNA-modifying protein (YTHDF2) that appears to drive inflammatory signaling and pyroptotic cell death in lab models of ulcerative colitis; targeting this pathway could open new avenues for...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of Molecular...
The study identifies a prebiotic-encapsulated extracellular vesicle approach that reduced colitis severity and early kidney stress in a mouse model, pointing to the gut microbiota and barrier function as key mediators....
If you have Crohn’s disease with perianal fistulas and are treated with infliximab, this study suggests the drug is cleared faster and trough levels are often lower after standard dosing — which may mean you need higher...
People hospitalized with acute severe ulcerative colitis face a high risk of steroid failure and need for rescue therapy or colectomy. This trial explores whether adding the JAK inhibitor tofacitinib to corticosteroids...
Patients and clinicians want blood or noninvasive tests that reflect what is seen on colonoscopy. This study identifies XCL1 as a blood biomarker candidate associated with endoscopic activity in Crohn's disease, though...
Accurate diagnosis and classification affect treatment choices and risks—misdiagnosis can lead to unnecessary immunosuppression, while misclassification can under-recognize severe or proximal disease that needs different...
Validated patient-reported measures help track how IBD affects daily function and well-being. A Turkish IBD-Disk gives clinicians and researchers a standardized way to measure patient-perceived disease burden and monitor...
The endoplasmic reticulum helps control cell metabolism and is implicated in conditions including metabolic disorders, cancer, and inflammatory diseases such as Crohn’s disease.
AHR signaling may influence epithelial inflammation in IBD and could be a potential target for future therapies or biomarker research. Findings are preliminary but point to IL‑8 as a responsive inflammatory mediator in...
The study describes a new small-molecule approach that reduced inflammation in mouse models of ulcerative colitis by targeting NF-κB transcription (p65 G-quadruplex). That suggests a potential future drug pathway...
This study describes a new preclinical approach to reduce inflammation in IBD by degrading NLRP3 rather than merely inhibiting it. For people following IBD therapeutic research, degraders could offer longer-lasting...
This change may make starting Skyrizi easier and more convenient by allowing induction to be done at home rather than IV infusions in a clinic. It expands options among IL‑23 p19 inhibitors for people with moderate to...
Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Risankizumab, IL-23 inhibitor, and Medications.
This gives adults with moderately to severely active Crohn’s disease a new at-home way to start Skyrizi treatment instead of needing an IV infusion, which can make initiation more convenient and fit into daily life.
This expands how risankizumab (an IL-23 inhibitor) can be started for adults with moderate-to-severe Crohn’s disease, allowing fully at-home, self-administered induction. That may make initiation easier and reduce clinic...
This study indicates pediatric DGBI are common worldwide and are linked to mental-health burden and healthcare use, so better recognition and support could help many children and families.
This analysis suggests delivery method for the same anti‑TNF (infliximab) may affect long‑term clinical and endoscopic outcomes in ileal-predominant Crohn’s disease. If confirmed, route of maintenance dosing could...
An FDA approval of a subcutaneous induction option for risankizumab means adults with moderate-to-severe Crohn's disease can start treatment at home using an on-body injector, which may make starting therapy more...
Definitions of "disease burden" vary a lot, which makes it hard to compare studies or to ensure care and research address what matters most to people with Crohn's. A unified, multidimensional framework could help...
The paper reports a preclinical targeted-delivery formulation that may allow lower systemic exposure to tofacitinib while concentrating drug in inflamed colon tissue—potentially reducing known systemic risks of JAK...
The study links common eating habits (fast food, fizzy drinks, spicy foods) with Crohn’s in this sample, which may help patients and clinicians think about dietary patterns worth discussing. It’s relevant because diet is...
This local profile highlights an IBD patient receiving scholarship support and speaking about living with Crohn’s, surgery (ostomy), and the broader immune-related effects of the disease. It may inspire patients,...
The study suggests two different ways to reduce inflammation in a mouse model of ulcerative colitis—one using a plant-derived compound that shifts beneficial microbes and metabolites, the other using an antibiotic that...
Long-term extension studies collect additional safety and tolerability information and can provide continued access to an investigational drug for people who were in the parent trials.
Hospitalized patients with moderate-to-severe ulcerative colitis flares sometimes need escalation to biologic or surgical treatments. This trial is testing whether a short course of HBOT can improve symptoms and reduce...
NUDT15 gene variants can strongly increase the risk of neutropenia from thiopurine drugs used in IBD. Knowing a child’s NUDT15 status could help prevent serious low white blood cell counts by guiding drug choice or...
The study points to creatine metabolism and CKB as regulators of intestinal epithelial health and shows hucMSC-derived vesicles can restore metabolic balance and reduce inflammation in preclinical models—highlighting a...
Depression and IBD often co-occur; knowing that each can precede the other helps patients and clinicians monitor mental health and GI symptoms more proactively.
The study presents a single engineered probiotic that can detect intestinal inflammation and, when reprogrammed, deliver IL‑22‑Fc locally to promote mucosal healing in animal models — a potential future avenue for...
The study suggests a specific immune pathway (NOX2-driven ROS in M1-like macrophages) by which colitis can worsen periodontitis, pointing to a potential therapeutic target that could eventually benefit people with IBD...
Findings suggest a dietary-derived prebiotic (Poria cocos polysaccharides) may reduce experimental colitis by shifting the microbiome and bile acids toward anti-inflammatory signaling—an avenue that could inform future...
Upadacitinib is an approved oral JAK1 inhibitor with evidence for inducing and maintaining remission in moderate-to-severe Crohn's disease, including colonic-predominant disease. Patients and clinicians may consider it...
If epithelial cells keep lasting "memories" of past inflammation or microbial signals, that could help explain why some people with IBD have persistent barrier dysfunction, relapses, or incomplete mucosal recovery even...
Reliable, low‑cost lab methods to measure mesalazine in tablets help ensure pharmaceutical quality and correct dosing of 5‑ASA drugs used in ulcerative colitis and IBD.
This study tests a novel method to deliver healthy mitochondria to the gut lining and reports improved cellular energy, barrier function, and decreased oxidative stress in a mouse model of ulcerative colitis—suggesting a...
This study maps gene and microRNA changes linked to ulcerative colitis and tests how deleting STAT6 or treating mice with Corylus avellana extract shifts those molecular signatures. Identifying such molecular players may...
If baseline mucosal gene-expression patterns can identify patients more likely to achieve mucosal healing across drug classes, those patterns could eventually help personalize treatment selection or stratify patients in...
